Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R23.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R25.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R11.htm
EX-3.1 - Q Therapeutics, Inc.ex3-1.htm
EX-3.2 - Q Therapeutics, Inc.ex3-2.htm
EX-32.1 - Q Therapeutics, Inc.ex32-1.htm
EX-32.2 - Q Therapeutics, Inc.ex32-2.htm
EX-14.1 - Q Therapeutics, Inc.ex14-1.htm
EX-31.2 - Q Therapeutics, Inc.ex31-2.htm
EX-31.1 - Q Therapeutics, Inc.ex31-1.htm
10-Q - Q Therapeutics, Inc.form10q.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R15.htm
v2.4.0.6
Condensed Consolidated Statements of Operations (Unaudited) (USD $)
3 Months Ended 9 Months Ended 126 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Income Statement [Abstract]          
Grant revenue       $ 7,229 $ 10,173 $ 612,457
License fee and other revenues          14,400 282,900
Total revenues       7,229 24,573 895,357
Operating expenses:          
Research and development 283,141 9,309 764,810 286,739 9,648,382
General and administrative 317,961 257,530 1,049,249 598,203 8,710,396
Total operating expenses 601,102 266,839 1,814,059 884,942 18,358,778
Operating loss (601,102) (266,839) (1,806,830) (860,369) (17,463,421)
Other income (expense):          
Interest income 1,023    3,212    186,554
Interest expense (2,136) (542,648) (5,580) (544,339) (2,114,757)
Other income (expense) 769 0 2,130 1,588 150,118
Total other expense, net (344) (542,648) (238) (542,751) (1,778,085)
Loss before provision for income taxes (601,446) (809,487) (1,807,068) (1,403,120) (19,241,506)
Provision for income taxes               
Net loss $ (601,446) $ (809,487) $ (1,807,068) $ (1,403,120) $ (19,241,506)
Weighted average number of common shares outstanding - basic and diluted 24,685,193 4,193,203 24,679,417 4,193,203  
Net loss per common share - basic and diluted $ (0.02) $ (0.19) $ (0.07) $ (0.33)